GLP-1 medications (like semaglutide or tirzepatide) are designed to be injected subcutaneously (into fat) , and there are three approved injection sites: Abdomen Inject at least 2 inches (5 cm) away from the belly button Most commonly used Easy to access and rotate Consistent absorption Thigh Upper outer or front thigh Good alternative if the abdomen is sore Absorption may feel slightly slower for some people Upper arm Back of the upper arm (fatty area) Works well, especially with help Can be harder to reach on your own What matters most: Inject into fat, not muscle Rotate sites weekly Avoid scars, bruises, or irritated skin Evidence note: Studies show similar absorption and effectiveness across all approved sites when injections are done correctly
Phase 3 trials, such as TRANSCEND-T2D-1, have demonstrated clinically meaningful outcomes
MASH is the primary risk factor for progressive hepatic fibrosis and possibly cardiovascular disease and malignancy
When these conversions don't happen, then the body's blood stream is overloaded with a form of B12 it can't use or clear very quickly (hence you feel very bad afterwards)
Treatments like Mounjaro and Wegovy have been through rigorous clinical trials and are proven to support weight loss
Even at the lowest maintenance dose (5 mg), patients saw an average loss of 15% (34 lbs)
